The changing face of clostridium difficile in critical care

Nursing Critical Care

Volumn 8, Issue 3, 2013, Pages 26-34

  Novotne, Tammy A ^a   Kaseb, Hatem O ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; COLESTYRAMINE; DRUG METABOLITE; FIDAXOMICIN; IMMUNOGLOBULIN G; METRONIDAZOLE; OP 1118; PROBIOTIC AGENT; TOLEVAMER; UNCLASSIFIED DRUG; VANCOMYCIN;

ABDOMINAL RADIOGRAPHY; ANAEROBIC CELL CULTURE; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; CELL CULTURE CYTOTOXICITY NEUTRALIZATION ASSAY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; COST OF ILLNESS; CRITICALLY ILL PATIENT; CYTOTOXICITY; DIARRHEA; DISEASE SEVERITY; DISINFECTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; ENZYME IMMUNOASSAY; FECAL TRANSPLANTATION; FRAIL ELDERLY; HAND WASHING; HOSPITAL INFECTION; HUMAN; IMMUNOTHERAPY; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; INTENSIVE CARE; LENGTH OF STAY; NONHUMAN; NUCLEIC ACID AMPLIFICATION; NURSING INTERVENTION; PERSONAL HYGIENE; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; RECURRENT INFECTION; SERODIAGNOSIS; TRANSPLANTATION;

EID: 84879403426     PISSN: 1558447X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCN.0000429383.25720.13     Document Type: Article

References (51)

1. Kuntz JL, Yang M, Cavanaugh J, Saftlas AF, Polgreen PM. Trends in Clostridium difficile infection among peripartum women. Infect Control Hosp Epidemiol. 2010;31(5):532-534.
2. Unger JA, Whimbey E, Gravett MG, Eschenbach DA. The emergence of Clostridium difficile infection among peripartum women: a case-control study of a C. difficile outbreak on an obstetrical service. Infect Dis Obstet Gynecol. 2011;2011:267249.
3. Venugopal AA, Gerding DN, Johnson S. Clostridium difficile infection rates and spectrum of disease among peripartum women at one hospital from 2003 to 2007 with molecular typing analysis of recovered Clostridium difficile isolates. Am J Infect Control. 2011;39(3):206-211.
4. Rouphael NG, O'Donnell JA, Bhatnagar J, et al. Clostridium difficile-associated diarrhea: an emerging threat to pregnant women. Am J Obstet Gynecol. 2008;198(6):635.e1-636.e1.
5. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431-455.
6. Barbut F, Jones G, Eckert C. Epidemiology and control of Clostridium difficile infections in healthcare settings: an update. Curr Opin Infect Dis. 2011;24(4):370-376.
7. Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect. 2006;12(suppl 6):2-18.
8. Centers for Disease Control and Prevention (CDC). Vital signs: preventing Clostridium difficile infections. MMWR Morb Mortal Wkly Rep. 2012;61(9):157-162.
9. Lo Vecchio A, Zacur GM. Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol. 2012;28(1):1-9.
10. Hookman P, Barkin JS. Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol. 2009;15(13):1554-1580.
11. Vaishnavi C. Clostridium difficile infection: clinical spectrum and approach to management. Indian J Gastroenterol. 2011;30(6):245-254.
12. LaMont JT. Clostridium difficile in adults: epidemiology, microbiology, and pathophysiology. http://www.uptodate.com.
13. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004;171(5):466-472.
14. Indra A, Schmid D, Huhulescu S, et al. Characterization of clinical Clostridium difficile isolates by PCR ribotyping and detection of toxin genes in Austria, 2006-2007. J Medl Microbiol. 2008;57(Pt 6):702-708.
15. Goorhuis A, Bakker D, Corver J, et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis. 2008;47(9):1162-1170.
16. Shin BM, Kuak EY, Yoo HM, et al. Multicentre study of the prevalence of toxigenic Clostridium difficile in Korea: results of a retrospective study 2000-2005. J Med Microbiol. 2008;57(Pt 6):697-701.
17. Goncalves C, Decre D, Barbut F, Burghoffer B, Petit JC. Prevalence and characterization of a binary toxin (actin-specific ADP-ribosyltransferase) from Clostridium difficile. J Clin Microbiol. 2004;42(5):1933-1939.
18. Sebaihia M, Wren BW, Mullany P, et al. The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat Genet. 2006;38(7):779-786.
19. Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother. 2012;67(3):742-748.
20. Drudy D, Harnedy N, Fanning S, Hannan M, Kyne L. Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile. Infect Control Hosp Epidemiol. 2007;28(8):932-940.
21. Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis. 2007;45(12):1543-1549.
22. Morrison RH, Hall NS, Said M, et al. Risk factors associated with complications and mortality in patients with Clostridium difficile infection. Clin Infect Dis. 2011;53(12):1173-1178.
23. Lawrence SJ, Puzniak LA, Shadel BN, Gillespie KN, Kollef MH, Mundy LM. Clostridium difficile in the intensive care unit: epidemiology, costs, and colonization pressure. Infect Control Hosp Epidemiol. 2007;28(2):123-130.
24. Kim JW, Lee KL, Jeong JB, et al. Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea. World J Gastroenterol. 2010;16(28):3573-3577.
25. Girotra M, Kumar V, Khan JM, et al. Clinical predictors of fulminant colitis in patients with Clostridium difficile infection. Saudi J Gastroenterol. 2012;18(2):133-139.
26. Carter GP, Rood JI, Lyras D. The role of toxin A and toxin B in the virulence of Clostridium difficile. Trends Microbiol. 2012;20(1): 21-29.
27. Badger VO, Ledeboer NA, Graham MB, Edmiston CE Jr. Clostridium difficile: epidemiology, pathogenesis, management, and prevention of a recalcitrant healthcare-associated pathogen. JPEN J Parenter Enteral Nutr. 2012;36(6):645-662.
28. Chapin K. Discrepancies in testing recommendations for Clostridium difficile infection: updated review favors amplification test systems. Expert Rev Mol Diagn. 2012;12(3):223-226.
29. Carroll KC. Tests for the diagnosis of Clostridium difficile infection: the next generation. Anaerobe. 2011;17(4):170-174.
30. Thoeni RF, Cello JP. CT imaging of colitis. Radiology. 2006;240(3):623-638.
31. Huang H, Weintraub A, Fang H, Nord CE. Antimicrobial resistance in Clostridium difficile. Int J Antimicrob Agents. 2009; 34(6):516-522.
32. Malkan AD, Scholand SJ. Preventing downstream Clostridium difficile infections with upstream antibiotic management. Med Hypotheses. 2012;78(1):136-137.
33. Crawford T, Huesgen E, Danziger L. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection. Amer J Health-Syst Pharm. 2012;69(11):933-943.
34. Metronidazole (Flagyl) prescribing information. Pfizer, Inc., April 2010. http://labeling.pfizer.com/ShowLabeling.aspx?id=570.
35. Fidaxomicin (Dificid) for Clostridium difficile infection. Med Lett Drugs Ther. 2011;53(1373):73-74.
36. FDA approves treatment for Clostridium difficile infection. 2011. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm257024.htm? utm-campaign.
37. Lancaster JW, Matthews SJ. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections. Clin Ther. 2012;34(1):1-13.
38. Gualtieri M, Villain-Guillot P, Latouche J, Leonetti JP, Bastide L. Mutation in the Bacillus subtilis RNA polymerase beta' subunit confers resistance to lipiarmycin. Antimicrob Agents Chemother. 2006;50(1):401-402.
39. Babakhani F, Gomez A, Robert N, Sears P. Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. J Med Microbiol. 2011;60(Pt 8):1213-1217.
40. Mayhew MS. Clostridium difficile treatment. J Nurse Practitioners. 2011;7(7):602-603.
41. Weiss K. Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer. Int J Antimicrob Agents. 2009;33(1):4-7.
42. Hinkson PL, Dinardo C, DeCiero D, Klinger JD, Barker RH Jr. Tolevamer, an anionic polymer, neutralizes toxins produced by the BI/027 strains of Clostridium difficile. Antimicrob Agents Chemother. 2008;52(6):2190-2195.
43. Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev. 2008(1):CD004611.
44. Yoon SS, Brandt LJ. Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients. J Clin Gastroenterol. 2010;44(8):562-566.
45. Musgrave CR, Bookstaver PB, Sutton SS, Miller AD. Use of alternative or adjuvant pharmacologic treatment strategies in the prevention and treatment of Clostridium difficile infection. Int J Infect Dis. 2011;15(7):e438-e448.
46. Guo B, Harstall C, Louie T, Veldhuyzen van Zanten S, Dieleman LA. Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease. Aliment Pharmacol Ther. 2012;35(8):865-875.
47. Noren T. Clostridium difficile and the disease it causes. Methods Mol Biol. 2010;646:9-35.
48. Valiquette L, Cossette B, Garant MP, Diab H, Pepin J. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis. 2007;45(suppl 2):S112-S121.
49. Deshpande A, Pant C, Pasupuleti V, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(3):225-233.
50. O'Donoghue C, Kyne L. Update on Clostridium difficile infection. Curr Opin Gastroenterol. 2011;27(1):38-47.
51. Schmidt ML, Gilligan PH. Clostridium difficile testing algorithms: what is practical and feasible? Anaerobe. 2009;15(6):270-273.